Dear Colleague,

Speaker Nancy Pelosi’s government takeover of prescription drug pricing couldn’t be more wrong for this historic time. As you know, she introduced H.R. 3 in the previous Congress—before the COVID-19 pandemic. It was bad policy then, and it’s even worse policy today for the hardworking people of this country who are seeking normalcy and an improved quality of life. The pandemic has further proven we can’t let the Speaker’s government price control scheme stop the development of lifesaving cures and treatments. That’s a tough sell for her on H.R. 3—perhaps that’s why she floated jamming it through as part of President Biden’s “infrastructure” plan.

Speaker Pelosi’s government price control scheme is the wrong way to lower drug costs. It would make America more reliant on Chinese medical manufacturing, which proved to be a major Achilles’ heel during the pandemic. It would lead to fewer cures and lifesaving medical breakthroughs—especially for families most in need of hope. If H.R. 3 were the law of the land before the pandemic, it would have hindered America’s private sector medical innovators from stepping up to help us beat the virus. Additionally, Speaker Pelosi’s policies would devalue people with disabilities and chronic illnesses—meaning they won’t have access to the treatments they need or those treatments will be delayed. For many patients, this delay in treatment could mean the difference between life and death.

We want to protect Americans’ health with effective cures, treatments, and therapies. That’s why Speaker Pelosi’s radical plan to put the federal government in charge of setting the price of prescription drugs cannot be our future.

After experiencing the greatest health and economic crises of our lifetime, people are eager for a modernized health care system, increased choice and transparency, and lower costs. That’s why we are leading H.R. 19, the Lower Costs, More Cures Act. We sent 15 bipartisan solutions from the Lower Costs, More Cures Act to President Donald Trump’s desk to become law last Congress. The updated bill we are introducing today reflects those achievements. All the provisions in H.R. 19 are bipartisan and are ready to become law as soon as possible, including two that already passed the People’s House last week.
H.R. 19, the Lower Costs, More Cures Act:

- Lowers costs without jeopardizing cures.
- Leads to lifesaving new cures and innovation, promotes more low-cost options for patients who need them, and stops drug companies from gaming the system.
- Doesn’t make America more reliant on China.
- Provides first-ever out-of-pocket cap for seniors in the Medicare Part D program.
- Caps the cost of insulin for seniors in the Medicare Part D program.
- Empowers patients with more drug price transparency and removes uncertainty at the pharmacy counter.
- Cuts the cost of cancer treatment and other drug administration for Medicare beneficiaries by as much as half.
- Enables strong, pro-America trade agreements to end American subsidizing of other developed countries’ health care.

To win the future, we must lead on lowering health care costs, upholding the dignity and right of every person to live a full life, and providing hope by ushering Americans into a new era of American innovation. Let’s lead with the American way, and stop Speaker Pelosi’s unpopular scheme that empowers China and government bureaucrats, and leads to fewer cures and less security.

We ask for your support and co-sponsorship of H.R. 19, the Lower Costs, More Cures Act.

Sincerely,

Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce

Virginia Foxx
Republican Leader
Committee on Education and Labor

Kevin Brady
Republican Leader
Committee on Ways and Means